PureTech Health PLC (PRTC)

NASDAQ: PRTC · IEX Real-Time Price · USD
29.49
-0.25 (-0.86%)
At close: Aug 18, 2022 3:14 PM
29.70
+0.22 (0.73%)
After-hours: Aug 18, 2022 4:00 PM EDT
-0.86%
Market Cap 838.42M
Revenue (ttm) 17.39M
Net Income (ttm) -60.56M
Shares Out 28.44M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,971
Open 30.99
Previous Close 29.74
Day's Range 29.49 - 31.65
52-Week Range 18.15 - 56.46
Beta 1.09
Analysts Buy
Price Target 84.98 (+188.2%)
Earnings Date Apr 21, 2022

About PRTC

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation p... [Read more...]

Industry Biotechnology
CEO Daphne Zohar
Employees 95
Stock Exchange NASDAQ
Ticker Symbol PRTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for PRTC stock is "Buy." The 12-month stock price forecast is 84.98, which is an increase of 188.21% from the latest price.

Price Target
$84.98
(188.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022.

PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc....

PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstratin...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results

PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

Other symbols: DNAA

Vedanta Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that...

PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances L...

BOSTON--(BUSINESS WIRE)--PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)

PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and C...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility

Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies B...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the ...

PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

BOSTON--(BUSINESS WIRE)--PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

BOSTON--(BUSINESS WIRE)--PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that ...

PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of Presid...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc....

PureTech to Present at the Jefferies Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Healthcare Conference

PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World T...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

Other symbols: RBLX

PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the ...

PureTech to Present at the UBS Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the UBS Global Healthcare Conference

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

BOSTON--(BUSINESS WIRE)--PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

PureTech Announces Share Buyback Program Update

BOSTON--(BUSINESS WIRE)--PureTech Announces Share Buyback Program Update

PureTech Announces Share Buyback Program of up to $50 Million

BOSTON--(BUSINESS WIRE)--PureTech Announces Share Buyback Program of up to $50 million

PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabet...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and T2D Presented at ECO 2022

PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the G...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota in New Study

PureTech Announces Annual Results for Year Ended December 31, 2021

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2021

PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Micro...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences announced the publication in the journal Cell Host & Microbe of the results from a study for VE303

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planne...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the p...